ClinicalTrials.gg
CompletedNCT02514551Updated Jun 17, 2020Results posted

A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

A Phase 2 interventional study of Ramucirumab and Paclitaxel in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing ramucirumab in Stomach Neoplasms — 3 open to participants now, 4 under way, none of them phase 3. Ramucirumab · Stomach Neoplasms.

Enrollment
4th of 20
245 · median 59
Started
2015
with 1 other
Phase 2
10 of 20
1 open now
Registered
6th of 20
by date
Lead sponsor
6 of 20
Eli Lilly and Company

Among the 20 studies testing ramucirumab in Stomach Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 2, and was the 6th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

3 of the 20 studies testing ramucirumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing ramucirumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).

03

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • stomach cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of gastric or GEJ adenocarcinoma.
  • The participant has disease progression during or within 4 months after last dose of chemotherapy or during or within 6 months after the last dose of or adjuvant therapy.
  • The participant received combination chemotherapy, which must include a platinum and/or a fluoropyrimidine and must not include a taxane or antiangiogenic agent.
  • The disease is evaluable by imaging per 1.1.
  • The participant has an performance status of 0 or 1.
  • The participant has adequate organ function:

    • Total ≤1.5 × the (ULN) and (ALT) and aspartate aminotransferase (AST) ≤3 × ULN. If the liver has tumor involvement, AST and ALT \<5 × ULN.
    • Serum creatinine ≤1.5 × ULN or calculated ≥50 milliliters/minute.
    • Urinary protein is \<2+.
    • ≥1.5 × 10\^9/liter (L), ≥100 × 10\^9/L, and ≥9 grams/deciliter (5.58 millimoles/L).
    • ≤1.5 × ULN and partial thromboplastin time ≤5 seconds above ULN.
  • The participant has an estimated of minimum 12 weeks.
  • The participant has resolution to Grade 1 or less by Version 4.0, of all toxic effects of previous therapy.
  • The participant, if male, is sterile or agrees to use a reliable method of .
  • The participant, if female, is surgically sterile, is , or agrees to use a highly effective method of birth control.
  • The participant, if female and of , must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • The participant is receiving therapy with any of the following:

    • Nonsteroidal anti-inflammatory agents.
    • Other anti- agents; Aspirin use at doses up to 325 milligrams (mg)/day is permitted.
  • The participant received radiotherapy within 14 days prior to randomization.
  • The participant received previous chemotherapy with a cumulative dose of >900 mg per meter squared (mg/m\^2) of epirubicin or >400 mg/m\^2 of doxorubicin.
  • The participant has documented or .
  • The participant has a significant bleeding disorder or vasculitis.
  • The participant experienced any arterial thromboembolic event within 6 months.
  • The participant has symptomatic congestive heart failure or symptomatic cardiac arrhythmia.
  • The participant has uncontrolled hypertension, despite antihypertensive intervention.
  • The participant underwent major surgery within 28 days.
  • The participant has a history of gastrointestinal perforation or fistula within 6 months.
  • The participant has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months.
  • The participant has bowel obstruction or history of chronic diarrhea that is considered .
  • The participant has either of the following:

    • B or C cirrhosis.
  • The participant has a serious illness or medical condition including:

    • infection.
  • The participant has a concurrent active other than the following:

    • Nonmelanomatous skin cancer.
    • In situ carcinoma of the cervix or other noninvasive carcinoma or in situ neoplasm.
  • The participant has a serious nonhealing: (a) wound, (b) peptic ulcer, or (c) bone fracture.
  • The participant experienced any Grade 3 or 4 venous thromboembolic event that is not adequately treated.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    12mg/kg Ramucirumab + 80 mg/m² Paclitaxel

    12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.

    Drug: Ramucirumab · Drug: Paclitaxel

  • Active comparator
    8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel

    8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.

    Drug: Ramucirumab · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ

    PFS was defined as time from the date of randomization(RD) to date of radiographic documentation of progression(RDP) or the date of death due to any cause, whichever is earlier as defined by RECIST v.1.1. Participants with no tumor progression and no death were censored at date of last adequate radiological assessment (AST) or date of RD(whichever is later).PD is at least a 20% increase in sum of diameters of target lesions,taking as reference the smallest sum on study.In addition to the relative increase of 20%,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.Non-Target PD is unequivocal progression of existing nontarget lesions.A participant with incomplete baseline disease had PFS time censored at the enrollment date.A participant not known to have died or have RDP as of the data inclusion cutoff date for the analysis had PFS time censored at date of the last complete RDP-free disease AST.

    Time frame: Randomization to Objective Progressive Disease or Death (Up To 21 Months)

Secondary outcomes

  1. Progression Free Survival (PFS) Ramucirumab 12mg/kg Arm and 8mg/kg Arm in I4T-MC-JVCZ

    PFS was defined as time from the date of randomization(RD) to date of radiographic documentation of progression(RDP) or the date of death due to any cause, whichever is earlier as defined by RECIST v.1.1. Participants with no tumor progression and no death were censored at date of last adequate radiological assessment(AST) or date of RD(whichever is later).PD is at least a 20% increase in sum of diameters of target lesions,taking as reference the smallest sum on study.In addition to the relative increase of 20%,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.Non-Target PD is unequivocal progression of existing nontarget lesions.A participant with incomplete baseline disease had PFS time censored at the enrollment date.A participant not known to have died or have RDP as of the data inclusion cutoff date for the analysis had PFS time censored at date of the last complete RDP-free disease AST.

    Time frame: Randomization to Objective Progressive Disease or Death (Up To 21 Months)

  2. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Combination With Paclitaxel

    Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Combination with Paclitaxel

    Time frame: Cycle(C) 1 Day(D) 1: Prior to Infusion(PTI),1 to 1.5 hours(hrs) after end of Infusion(EOI); C1 D15: 3 days PTI; C2 D1: 3 days PTI; C2 D15: 3 days PTI,1 to 1.5 hrs after EOI; C3 D1 and 15: 3 days PTI; C4 D1: 3 days PTI and 1 to 1.5 hrs after EOI

  3. Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])

    ORR was defined as the percentage of participants who achieved a PR or CR per RECIST v.1.1.CR is the disappearance of all target lesions.Any pathological lymph nodes(whether target or non-target)must have reduction in short axis to\<10mm.Tumor marker results must have normalized.PR is at least a 30% decrease in the sum of diameter of target lesions,taking as reference the baseline sum diameters.ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.

    Time frame: Baseline to Objective Progressive Disease (Up To 21 Months)

  4. Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) [Disease Control Rate (DCR)]

    DCR is defined as the percentage of participants who achieved CR, PR, or SD per RECIST v.1.1. CR is the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm.Tumor marker results must have normalized. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression. Non-Target PD is unequivocal progression of existing nontarget lesions. DCR=CR+PR+SD/total number of participants\*100.

    Time frame: Baseline to Objective Progressive Disease (Up To 21 Months)

  5. Number of Participants With Anti-Ramucirumab Antibodies

    Participants who had anti-ramucirumab antibodies at postbaseline.

    Time frame: Cycle 1 Predose through Follow-up (Up To 24 Months)

07

Results

Posted Dec 19, 2018

Participant flow

Participant flow — Overall Study
Milestone12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Started123122
Received at least one dose of study drug123120
Completed123119
Not completed03
Withdrew: Lost to follow-up01
Withdrew: Participant never treated02

Outcome measures

PrimaryProgression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ

PFS was defined as time from the date of randomization(RD) to date of radiographic documentation of progression(RDP) or the date of death due to any cause, whichever is earlier as defined by RECIST v.1.1. Participants with no tumor progression and no death were censored at date of last adequate radiological assessment (AST) or date of RD(whichever is later).PD is at least a 20% increase in sum of diameters of target lesions,taking as reference the smallest sum on study.In addition to the relative increase of 20%,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.Non-Target PD is unequivocal progression of existing nontarget lesions.A participant with incomplete baseline disease had PFS time censored at the enrollment date.A participant not known to have died or have RDP as of the data inclusion cutoff date for the analysis had PFS time censored at date of the last complete RDP-free disease AST.

Time frame:
Randomization to Objective Progressive Disease or Death (Up To 21 Months)
Reported as:
Median · months
Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ
monthsI4T-MC-JVCZ: 12mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Progression Free Survival (PFS) in Ramucirumab 12mg/kg Arm I4T-MC-JVCZ5.42 (4.40 to 6.01)
Statistical analysis
  • I4T-MC-JVCZ: 12mg/kg Ramucirumab + 80 mg/m² Paclitaxel · Hazard ratio (hr): 0.617 · 95% CI 0.447 to 0.853Unstratified cox proportional hazards model comparing Ramucirumab I4T-MC-JVCZ and I4T-IE-JVBE (NCT01170663)
SecondaryProgression Free Survival (PFS) Ramucirumab 12mg/kg Arm and 8mg/kg Arm in I4T-MC-JVCZ

PFS was defined as time from the date of randomization(RD) to date of radiographic documentation of progression(RDP) or the date of death due to any cause, whichever is earlier as defined by RECIST v.1.1. Participants with no tumor progression and no death were censored at date of last adequate radiological assessment(AST) or date of RD(whichever is later).PD is at least a 20% increase in sum of diameters of target lesions,taking as reference the smallest sum on study.In addition to the relative increase of 20%,the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.Non-Target PD is unequivocal progression of existing nontarget lesions.A participant with incomplete baseline disease had PFS time censored at the enrollment date.A participant not known to have died or have RDP as of the data inclusion cutoff date for the analysis had PFS time censored at date of the last complete RDP-free disease AST.

Time frame:
Randomization to Objective Progressive Disease or Death (Up To 21 Months)
Reported as:
Median · months
Progression Free Survival (PFS) Ramucirumab 12mg/kg Arm and 8mg/kg Arm in I4T-MC-JVCZ
months12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Progression Free Survival (PFS) Ramucirumab 12mg/kg Arm and 8mg/kg Arm in I4T-MC-JVCZ5.42 (4.40 to 6.01)5.16 (3.81 to 5.65)
Statistical analysis
  • 12mg/kg Ramucirumab + 80 mg/m² Paclitaxel vs 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel · Hazard ratio (hr): 0.963 · 95% CI 0.727 to 1.274Unstratified cox proportional hazards model.
SecondaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Combination With Paclitaxel

Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Combination with Paclitaxel

Time frame:
Cycle(C) 1 Day(D) 1: Prior to Infusion(PTI),1 to 1.5 hours(hrs) after end of Infusion(EOI); C1 D15: 3 days PTI; C2 D1: 3 days PTI; C2 D15: 3 days PTI,1 to 1.5 hrs after EOI; C3 D1 and 15: 3 days PTI; C4 D1: 3 days PTI and 1 to 1.5 hrs after EOI
Reported as:
Geometric mean · Microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Combination With Paclitaxel
Microgram per milliliter (µg/mL)12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Cycle 1 Day 15 (Week 2)39.2 ± 4321.4 ± 58
Cycle 2 Day 1 (Week 4)63.6 ± 4037.1 ± 50
Cycle 2 Day 15 (Week 6)76.7 ± 4243.5 ± 53
Cycle 3 Day 1(Week 8)91.2 ± 4051.5 ± 55
Cycle 3 Day 15 (Week 10)99.0 ± 4452.9 ± 56
Cycle 4 Day 1 (Week 12)101 ± 5556.1 ± 56
SecondaryPercentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])

ORR was defined as the percentage of participants who achieved a PR or CR per RECIST v.1.1.CR is the disappearance of all target lesions.Any pathological lymph nodes(whether target or non-target)must have reduction in short axis to\<10mm.Tumor marker results must have normalized.PR is at least a 30% decrease in the sum of diameter of target lesions,taking as reference the baseline sum diameters.ORR is calculated as a total number of participants with CR or PR divided by the total number of participants treated multiplied by 100.

Time frame:
Baseline to Objective Progressive Disease (Up To 21 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])
percentage of participants12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR])27.625.4
SecondaryPercentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) [Disease Control Rate (DCR)]

DCR is defined as the percentage of participants who achieved CR, PR, or SD per RECIST v.1.1. CR is the disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm.Tumor marker results must have normalized. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression. Non-Target PD is unequivocal progression of existing nontarget lesions. DCR=CR+PR+SD/total number of participants\*100.

Time frame:
Baseline to Objective Progressive Disease (Up To 21 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) [Disease Control Rate (DCR)]
percentage of participants12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) [Disease Control Rate (DCR)]78.975.4
SecondaryNumber of Participants With Anti-Ramucirumab Antibodies

Participants who had anti-ramucirumab antibodies at postbaseline.

Time frame:
Cycle 1 Predose through Follow-up (Up To 24 Months)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Ramucirumab Antibodies
Participants12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Number of Participants With Anti-Ramucirumab Antibodies21

Adverse events

Collected over Up To 40 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12mg/kg Ramucirumab + 80 mg/m² Paclitaxel81/123 (65.9%)47/123 (38.2%)117/123 (95.1%)
8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel76/120 (63.3%)32/120 (26.7%)115/120 (95.8%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
Event12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
Neutrophil count decreasedInvestigations6/1230/120
Febrile neutropeniaBlood and lymphatic system disorders4/1233/120
Abdominal painGastrointestinal disorders4/1232/120
AnaemiaBlood and lymphatic system disorders3/1233/120
Gastric haemorrhageGastrointestinal disorders3/1231/120
VomitingGastrointestinal disorders3/1231/120
IleusGastrointestinal disorders0/1232/120
Gastrointestinal haemorrhageGastrointestinal disorders2/1230/120
AstheniaGeneral disorders2/1230/120
General physical health deteriorationGeneral disorders2/1230/120
Most frequent other events
Showing 10 of 45
Most frequent other events
Event12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel
FatigueGeneral disorders43/12346/120
AnaemiaBlood and lymphatic system disorders34/12339/120
NauseaGastrointestinal disorders27/12338/120
DiarrhoeaGastrointestinal disorders31/12335/120
Decreased appetiteMetabolism and nutrition disorders25/12332/120
Neutrophil count decreasedInvestigations30/12324/120
VomitingGastrointestinal disorders29/12327/120
EpistaxisRespiratory, thoracic and mediastinal disorders26/12328/120
NeutropeniaBlood and lymphatic system disorders22/12324/120
AlopeciaSkin and subcutaneous tissue disorders19/12324/120

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelTotal
Mean58.6 ± 11.457.9 ± 12.358.3 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelTotal
Female404484
Male8378161
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelTotal
Hispanic or Latino8715
Not Hispanic or Latino110108218
Unknown or Not Reported5712
Race (NIH/OMB)
Race (NIH/OMB)(Participants)12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelTotal
American Indian or Alaska Native101
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American224
White119117236
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)12mg/kg Ramucirumab + 80 mg/m² Paclitaxel8 mg/kg Ramucirumab + 80 mg/m² PaclitaxelTotal
Greece101121
Canada044
Sweden112
Turkey241640
Belgium6511
United States16824
Czechia7916
Ukraine182644
Italy16723
Germany224
Spain233356
08

Study locations

52 sites
  • City of Hope National Medical Center
    Duarte, California 91010-0269, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66205, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Scott & White Memorial Hospital & Clinic
    Temple, Texas 76508, United States
  • Vista Oncology Inc. PS
    Olympia, Washington 98502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kortrijk, 8500, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Namur, 5000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Calgary, T2N 4N2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Oshawa, L1G 2B9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brno, 656 53, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Novy Jicin, 741 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha, 140 59, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha, 150 06, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13353, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt am Main, 60488, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20246, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ravensburg, 88212, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 18537, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haidari, 12462, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heraklion, 71110, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    N. Efkarpia, 56403, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26504, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cagliari, 09042, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cremona, 26100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Faenza, 48018, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20089, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reggio Emilia, 42100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Giovanni Rotondo, 71013, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08208, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 17007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Girona, 17007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28041, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28050, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malaga, 29010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santander, 39008, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goteborg, 413 56, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Linkoping, 58185, Sweden
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ankara, 06100, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edirne, 22770, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Istanbul, 34098, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kayseri, 38039, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malatya, 44280, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dnipropetrovsk, 49102, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyiv, 04107, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lutsk, 63000, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sumy, 40005, Ukraine
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vinnitsa, 21029, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Oct 2017, 24 months.

Results were first posted in Dec 2018, 1 year 1 month after primary completion.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 24 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2015
First posted
Aug 3, 2015
StartActual
Oct 12, 2015
Primary completionActual
Oct 27, 2017
CompletionActual
Dec 28, 2018
Results first posted
Dec 19, 2018
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02514551
Responsible party
Sponsor
First posted
Aug 3, 2015
Start date
Oct 12, 2015
Primary completion
Oct 27, 2017
Completion
Dec 28, 2018
Results posted
Dec 19, 2018
Last update
Jun 17, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Paclitaxel

Start the discussion